Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome

Inclusion Criteria

• •From 6 to 80 years old at time of consent.
• •Patients with the following haematological diseases:
• •* Acute myeloid leukaemia (de novo or secondary)
• •* Myelodysplastic syndromes (RAEB I/II)
• •* T-cell acute lymphoblastic leukaemia (T-ALL)
• •Patients must have been treated with prior standard intensive chemotherapy upfront, which will be defined according to institutional practice for each respective disease, and may include allogeneic haematopoietic stem cell transplantation.
• •Patients must have persistent detectable residual leukaemia following initial treatment with intensive chemotherapy. Residual leukaemia is defined as the presence of \>=0.01%-20% blasts in the bone marrow by flow cytometry.
• •* High risk AML patients with either High risk cytogenetics or FLT3-ITD mutation or Acute megakaryoblastic leukaemia in non-Down's Therapy related leukaemia or Myelodysplastic syndrome
• •will qualify for NKEXPSIN either after Induction I chemotherapy or Induction II chemotherapy regardless of residual disease.
• •At least two weeks since receipt of any biological therapy, chemotherapy, and/or radiation therapy.
• •Shortening fraction greater than or equal to 25%.
• •Glomerular filtration rate greater than or equal to 60ml/min.
• •Pulse oximetry greater than or equal to 92% on room air.
• •Direct bilirubin less than or equal to 3x Upper Limit of Normal (ULN).
• •Karnofsky performance score of greater than or equal to 50.
• •Has a suitable adult family member donor available for NK cell donation.
• •Ability to provide informed consent. Otherwise, a legally authorized representative (LAR) must be present throughout the consent process and is allowed to give consent on the patient's behalf.
• •At least 21 years old at time of consent.
• •A family member with a greater than or equal to 3 of 6 HLA match to recipient
• •Ability to provide informed consent. Otherwise, a legally authorized representative must be present throughout the consent process and is allowed to give consent on the patient's behalf.